Children's Mercy Kansas City

SHARE @ Children's Mercy
Manuscripts, Articles, Book Chapters and Other Papers
2-2022

Emerging Role of Clinical Genetics in CKD.
Prasad Devarajan
Glenn M. Chertow
Katalin Susztak
Adeera Levin
Rajiv Agarwal

See next page for additional authors

Follow this and additional works at: https://scholarlyexchange.childrensmercy.org/papers

Recommended Citation
Devarajan P, Chertow GM, Susztak K, et al. Emerging Role of Clinical Genetics in CKD. Kidney Med.
2022;4(4):100435. Published 2022 Feb 11. doi:10.1016/j.xkme.2022.100435

This Article is brought to you for free and open access by SHARE @ Children's Mercy. It has been accepted for
inclusion in Manuscripts, Articles, Book Chapters and Other Papers by an authorized administrator of SHARE @
Children's Mercy. For more information, please contact hlsteel@cmh.edu.

Creator(s)
Prasad Devarajan, Glenn M. Chertow, Katalin Susztak, Adeera Levin, Rajiv Agarwal, Peter Stenvinkel,
Arlene B. Chapman, and Bradley A. Warady

This article is available at SHARE @ Children's Mercy: https://scholarlyexchange.childrensmercy.org/papers/4360

Review

Emerging Role of Clinical Genetics in CKD
Prasad Devarajan, Glenn M. Chertow, Katalin Susztak, Adeera Levin, Rajiv Agarwal,
Peter Stenvinkel, Arlene B. Chapman, and Bradley A. Warady
Chronic kidney disease (CKD) afﬂicts 15% of adults in the United States, of whom 25% have a family
history. Genetic testing is supportive in identifying and possibly conﬁrming diagnoses of CKD, thereby
guiding care. Advances in the clinical genetic evaluation include next-generation sequencing with targeted gene panels, whole exome sequencing, and whole genome sequencing. These platforms provide
DNA sequence reads with excellent coverage throughout the genome and have identiﬁed novel genetic
causes of CKD. New pathologic genetic variants identiﬁed in previously unrecognized biological pathways
have elucidated disease mechanisms underlying CKD etiologies, potentially establishing prognosis and
guiding treatment selection. Molecular diagnoses using genetic sequencing can detect rare, potentially
treatable mutations, avoid misdiagnoses, guide selection of optimal therapy, and decrease the risk of
unnecessary and potentially harmful interventions. Genetic testing has been widely adopted in pediatric
nephrology; however, it is less frequently used to date in adult nephrology. Extension of clinical genetic
approaches to adult patients may achieve similar beneﬁts in diagnostic reﬁnement and treatment selection. This review aimed to identify clinical CKD phenotypes that may beneﬁt the most from genetic
testing, outline the commonly available platforms, and provide examples of successful deployment of
these approaches in CKD.

INTRODUCTION
Chronic kidney disease (CKD) is a major global health
problem and is increasing in prevalence.1 In the United
States, among the 15% of adults who have CKD, 25% may
have a family history.2 By 2040, it is estimated that CKD
will have become the fifth-leading cause of death in the
United States.3 CKD can be identified by well-established
clinical biomarkers, such as serum creatinine levels, cystatin C levels, estimated glomerular filtration rate, and
either urinary albumin-creatinine ratio or urinary proteincreatinine ratio4,5 as well as other emerging biomarkers
and devices.6,7 However, clinical biomarkers have limited
usefulness for determining the cause of CKD or the
probability of progression to kidney failure.8-11
Precision medicine in CKD is aimed at providing an
accurate diagnosis, establishing a prognosis, and appropriately individualizing treatment; however, these goals
have only been achieved in a few instances despite the high
heritability of CKD.8 Presently, approximately 625 genes
have been demonstrated to contribute to the development
of CKD,12 and it has been suggested that the heritability for
estimated glomerular filtration rate and albuminuria may
range from 36% to 75% and 16% to 49% of cases,
respectively.13 Toward that end, genetic evaluation is an
essential component of precision medicine and has the
potential to reduce clinical uncertainty of CKD.14 The
objective of this study was to review the role of clinical
genetics and next-generation sequencing (NGS) in patients
with CKD. It is particularly important to bridge the gap in
understanding the implications of clinical genetics across
the nephrology community, including pediatric and adult
nephrologists, because inherited disorders account for
varying cases of kidney failure across patient age groups.
Kidney Med Vol 4 | Iss 4 | Month 2022 | 100435
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ASSESSING GENETIC CONTRIBUTIONS TO
CKD
Not all patients with CKD need genetic testing. Some
common indications to consider for genetic testing are
illustrated in Fig 1. In many patients with CKD, the cause
of disease remains unclear despite a thorough evaluation.15
In these instances, genetic testing has the potential to
enable formal diagnosis and targeted intervention, as well
as reduce the utilization of medications with potential
significant side effects.16 Rare single nucleotide variants,
small insertion/deletion variants, and copy number variants underlie many Mendelian conditions, and rare kidney
diseases can be monogenic. In addition, interactions
among multiple genes often determine the clinical phenotypes.17,18 Reaching a definitive diagnosis may require
analyzing multiple genes—often from small specimens—inexpensively, quickly, and sensitively. One goal
of genetic association studies is to delineate the genetic
architecture of complex phenotypes and diseases, such as
CKD, to provide new insights into the best approaches to
patient management.19
In addition, genetic testing should be strongly considered when a genetic component is clinically suspected. For
example, the presence of a family history of CKD of unclear etiology should prompt genetic evaluation of not
only the index case but also other affected family members.10,17,20 Such information can be invaluable for
detection of disease in previously undiagnosed relatives,
family planning including preimplantation genetic testing,
and donor eligibility to evaluate family members as potential kidney donors.21 A genetic component should also
be suspected in patients with CKD at young age of onset
because nearly all pediatric cases that progress to kidney
1
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with CKD and hematuria with a family history of hematuria. A genetic diagnosis of one of the forms of Alport
syndrome may eliminate the need for invasive kidney biopsies in the index case as well as in family members.26
A genetic diagnosis can also be invaluable in personalizing therapeutic decisions. Patients with steroid-resistant
nephrotic syndrome due to a genetic etiology will
benefit from withholding potentially toxic immunosuppression, which is ineffective, but can be excellent candidates for kidney transplant when they progress to kidney
failure because the nephrotic syndrome may not recur in
the kidney transplant.20 Establishing the genetic diagnosis
also allows for specific therapeutic targeting of the affected
pathways, as exemplified by complement blockade in genetic forms of atypical hemolytic uremic syndrome (HUS)
and blocking oxalate metabolism in the primary hyperoxalurias.20,27-29 Increasingly, the confirmation of a genetic diagnosis is becoming essential to enroll patients in
pharmaceutical trials, especially in rare diseases such as
primary hyperoxalurias and atypical HUS associated with
expensive therapies.15
Figure 1. Indications for genetic testing in CKD. Clinical genetics should be considered in CKD if the etiology is unclear,
when a genetic component is clinically suspected (positive family
history, early onset, extrarenal manifestations, unusual disease
course), or to guide therapy (eg, immunosuppression management, pretransplant evaluation). Abbreviation: CKD, chronic kidney disease.

replacement therapy have genetic underpinnings.22 Patients with CKD and extrarenal manifestations are also at a
high risk of a genetic etiology, as exemplified by visual and
hearing disturbances in Alport syndrome, retinitis pigmentosa in nephronophthisis, and maturity-onset diabetes
of the young (MODY) in the kidney cysts and diabetes
syndrome.17,20,23 As a corollary, identification of a genetic
cause for CKD will prompt early referrals for early identification and prevention of known or potential extrarenal
manifestations.20,21
Even if a clinical diagnosis is strongly suspected, genetic
testing can be useful in confirming the diagnosis and
reclassifying the disease and in prognostication.10,21 For
example, patients with the clinical diagnosis of polycystic
kidney disease (PKD) can benefit from the determination
of the underlying genetic defect because those with truncating mutations in the PKD1 gene progress to kidney
failure, on average, in their 50s, whereas those with
nontruncating PKD1 mutations have an average age of
kidney failure onset in their 60s, and those with PKD2
mutations exhibit kidney survival until 80 years of age.24 It
is important to note, however, the lack of prognostic
specificity for individuals with autosomal dominant polycystic kidney disease (ADPKD) despite the population
means.25 Establishing a genetic diagnosis can also avoid
unnecessary tests and procedures, including in patients
2

NEXT-GENERATION SEQUENCING (NGS) TO
IDENTIFY GENES IN CKD: RECENT STUDIES
There are currently 3 NGS approaches—targeted panel
sequencing, whole exome sequencing (WES), and whole
genome sequencing (WGS)—that have been used to
improve the diagnosis of hereditary diseases, including
CKD (Fig 2).30,31 The relative strengths and weaknesses of
these approaches are shown in Table 1.32,33 The emergence of NGS has resulted in a large number of articles on
single-gene contributions to kidney disease.34 Several
hundred genes have now been identified that may
contribute to the development and progression of CKD.35
All NGS approaches listed have contributed to our understanding of specific genes and disease pathways involved in
CKD.
Targeted Gene Panels in CKD
Results from the PodoNet Registry, which is focused on
steroid-resistant nephrotic syndrome, showed that an
NGS-based panel approach that included >30 podocyterelated genes complemented by WES supported the
determination of genetic diagnoses in 24% of the patients
screened. It also extended the spectrum of genetic diseases
presenting with a steroid-resistant nephrotic syndrome
phenotype (mutation of the COL4A3-5 and CLCN5 genes),
as well as contributing to the discovery of new causative
genes (eg, MYOE1, PTPRO).36 NGS techniques have now
identified
>50
causal
genes
in
hereditary
podocytopathies.37
A targeted NGS panel covering 39 genes implicated in
focal segmental glomerulosclerosis (FSGS) and steroidresistant nephrotic syndrome—including COL4A3,
COL4A4, or COL4A5—was applied to 81 adults from 76
families (24 families with a history of kidney disease).38
Kidney Med Vol 4 | Iss 4 | Month 2022 | 100435
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Figure 2. Different approaches to genetic testing. Sanger sequencing is limited to a narrow portion of the genome. In targeted gene
panels, only coding portions of a speciﬁc set of genes are targeted. Whole exome sequencing captures almost all coding sequences,
and whole genome sequencing covers nearly all regions of the genome.

Pathogenic mutations were confirmed in 10 patients (6
with family history) from 9 families. The collagen type IV
mutations—evident in 8 patients from 6 families—represented 56% of definitely pathogenic mutations
and provided a diagnosis of Alport syndrome in 6 patients.
In addition, a histologic diagnosis of thin basement
membrane nephropathy, also a manifestation of a COL4A
mutation, was established in 2 patients. NGS identified
collagen gene mutations in 38% of families with familial
FSGS and 3% with sporadic FSGS; >50% of the mutations
occurred in COL4A5.38
The value of targeted gene panels has been demonstrated by a kidney disease gene panel that provides a
comprehensive and cost-effective approach to the genetic
diagnosis of patients with cystic and glomerular inherited kidney diseases. In a study of 421 patients with
known or suspected inherited kidney diseases, a 140gene kidney disease panel for the genetic diagnosis of
suspected cystic or glomerular inherited kidney diseases
was used for confirmation of disease diagnoses.39
Kidney Med Vol 4 | Iss 4 | Month 2022 | 100435

Patients were assigned to a validation cohort (n = 116)
with known mutations and a diagnostic cohort (n = 305)
with suspected inherited cystic (n = 207) or glomerular
(n = 98) diseases.39 Seventy-eight percent of cystic and
62% of glomerular cases in the diagnostic cohort had a
genetic cause.39 In patients suspected to have cystic
inherited kidney disease, genetic analysis provided
diagnosis in 25 of 31 prenatal (81%), 46 of 64 pediatric
(72%), and 90 of 112 adult patients (80%).39 In those
with suspected glomerular inherited kidney diseases, all
5 patients with congenital-onset glomerular inherited
kidney disease (detected in the perinatal period), 26 of
50 pediatric patients (52%), and 30 of 43 adult patients
(70%) achieved a molecular diagnosis.39 A high level of
sensitivity (99%) was reported in the validation cohort
with 134 of 135 previously known mutations accurately
detected.39 This panel allowed an etiologic diagnosis in
75% of patients and was particularly useful in those with
nonspecific or atypical phenotypes.39 For example, in
patients with nonspecific cystic disease of unknown
3
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Table 1. Comparison of Next-Generation DNA Sequencing Strategies32
Strengths

Weaknesses

Targeted Panels
• Readily standardizable
• Rapid interpretation for
clinical use
• Low costs
• Easy clinical
implementation

Whole Exome Sequencing
• Detection of CNVs
• Research applications
• Feasible in clinical routine
• Low price/performance
ratio

• Limited, “peephole”
observations
• Limited value for
research
• Limited assessment of
complex aberrations

• Not fully comprehensive
• Lower CNV resolution
• Ampliﬁcation or exon
capture necessary
• High bioinformatic effort
• Demanding clinical
interpretation
• Time-consuming workﬂow

Whole Genome Sequencing
• Comprehensive assessment of entire genomes
• Highest resolution of genomic alterations
• SNVs in enhancer/promoter and ncRNA regions
• Accurate characterization of CNVs, offering position
and orientation information; possibility of false-positive
results due to incorrect or ambiguous mapping of
sequence reads to the reference genome33
• Decreasing costs
• Subject to future studies
• Uncertain value for clinical interpretation
• Most expensive

Note: This table (modiﬁed from original) is used under a Creative Commons CC BY-NC 4.0 License speciﬁc to the article published by Elsevier Limited on behalf of the
European Society for Medical Oncology: Horak P, Fr€
ohling S, Glimm H. Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls.
ESMO Open. 2016;1:e000094. https://doi.org/10.1136/esmoopen-2016-000094.
Abbreviations: CNV, copy number variant; ncRNA, noncoding RNA; SNV, single nucleotide variant.

etiology, nearly 70% were shown to have ADPKD by
genetic analysis.39
Gribouval et al40 studied 135 patients with adult-onset
steroid-resistant nephrotic syndrome and/or FSGS who
were highly selected for potentially nonimmune FSGS. An
NGS panel that screened for 35 genes was used.40 Pathogenic mutations were found in 30 patients (22.2%),
including 16 (11.8%) with mutations in known monogenic SRNS genes and 14 (10.4%) with mutations in APOL1
alleles at high risk. Of the 16 patients with monogenic
steroid-resistant nephrotic syndrome mutations, 7
(43.7%) had mutations in COL4A.40 These findings are
consistent with prior results indicating that COL4A mutations were the most frequent type of mutation in FSGS.38
Another study on NGS examined variants in a panel of
109 genes associated with FSGS, nephrotic syndrome,
congenital anomalies of the kidney and urinary tract, or
nephronophthisis. Study participants included probands
with a pathologic diagnosis of FSGS and relatives with
>500-mg protein excretion per day, comprising 193 individuals from 179 families. Forty-three patients were familial cases belonging to 29 pedigrees and 150 were
sporadic. The cohort had 56% men (51% in the familial
cases and 57% in the sporadic cases). The mean age of
disease onset was 34 years, and 78% of the patients presented with normal kidney function.41 The overall diagnostic rate was 11% (20 of 179 families). This rather low
diagnostic rate may still be considered clinically significant
because a genetic etiology had not been previously identified in this cohort, with important implications for
guiding immunosuppressive therapies as well as planning
for a future kidney transplant. Surprisingly, pathogenic
variants in COL4A3, COL3A3, or COL4A5 accounted for 55%
(11 of 20) of cases attributed to a single gene, with most
found in COL4A5. It was concluded that FSGS is commonly
the result of COL4A disorders, as well as podocyte and
4

kidney developmental defects.41 Table 2 summarizes key
results from the studies discussed in this section.42,43
Whole Exome Sequencing (WES) in CKD
Whereas targeted sequencing is often restricted to select
predetermined gene panels, the WES approach allows for
interrogation of the entire exome, thereby identifying
previously unknown variants.10 WES in CKD has been
instrumental in identifying mutations in heterogeneous
CKD cohorts and in known clinical groups (eg, nephronophthisis and medullary cystic kidney disease), as
shown in Table 3.44-49
A pilot study assessed the diagnostic utility of WES in a
selected referral population of 92 adults with CKD of unknown cause, familial nephropathy, or hypertension.45
WES provided a diagnosis encompassing 13 distinct genetic disorders in 24% of these patients, 9 of whom were
probands with an unknown cause of CKD. Loss-offunction mutations were identified in poly(A)-specific
ribonuclease in 2 probands with tubulointerstitial
fibrosis. Poly(A)-specific ribonuclease mutations have been
previously detected in a syndrome that includes lung, bone
marrow, and liver fibrosis; these findings implicate
poly(A)-specific ribonuclease mutations in kidney
fibrosis.45 The genetic results influenced treatment in most
patients and included targeted surveillance, familial
screening to aid donor selection for transplant, and
changes in medication.45 A small-scale study used WES to
identify genetic factors associated with diabetic kidney
disease. Nine MODY probands with biopsy-proven diabetic kidney disease were included in this study. WES was
used to determine suspected MODY probands and their
families.46 Individuals from 9 families had a diagnosis of
HNF1B-MODY, CEL-MODY, PAX4-MODY, and WFS1MODY; 196 selected variants of 25 genes associated with
increased susceptibility to diabetic kidney disease were
Kidney Med Vol 4 | Iss 4 | Month 2022 | 100435
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Table 2. Results With Targeted Gene Panels in CKD
Study
Rasouly et al 201912

Participants
A convenience sample of exome sequence data
from 7,974 self-declared healthy adults

Trautmann et al 201836

Registry including >2,000 pediatric patients
with steroid-resistant nephrotic syndrome

Bullich et al 201839

421 patients with known or suspected inherited
kidney diseases
81 adults from 76 families (24 families with a
history of kidney disease)

Gast et al
201638
Gribouval et al 201840

135 patients with adult-onset steroid-resistant
nephrotic syndrome and/or FSGS

Yao et al
201941

Probands with a pathologic diagnosis of FSGS
and relatives with >500-mg protein excretion/
d (total of 193 individuals from 179 families)

Papazachariou et al 201742

24 families with members having familial
microscopic hematuria assessed for the
presence of one of a genetically heterogeneous
group of conditions, including the collagen IV
nephropathies, heritable complement C3/
CFHR5 nephropathy, and glomerulopathy with
ﬁbronectin deposits
212 patients with suspected ADPKD

Mantovani et al 202043

Key Results
Evaluation of the prevalence of candidate
pathogenic variants in 625 genes correlated
with Mendelian kidney and genitourinary
disorders. In total, 23.3% had a candidate
pathogenic variant, most of which were due to
previously reported variants with high allele
frequencies.
NGS-based gene panel screening with >30
podocyte-related genes complemented by
WES achieved genetic diagnoses in 24% of the
patients screened, broadened the spectrum of
genetic disease entities presenting with steroidresistant nephrotic syndrome phenotype
(COL4A3-5, CLCN5), and added to the
discovery of new disease causative genes
(MYOE1, PTPRO).
78% of cystic and 62% of glomerular cases in
the diagnostic cohort had a genetic cause.
NGS identiﬁed collagen gene mutations in 38%
of families with familial FSGS, and 3% with
sporadic FSGS; >50% of the mutations
occurred in COL4A5.
Pathogenic mutations were found in 30
patients (22%), including 16 (12%) with
mutations in known monogenic SRNS genes
and 14 (10%) with APOL1 alleles at high risk.
Of the 16 patients with monogenic steroidresistant nephrotic syndrome mutations, 7
(44%) had mutations in COL4A.
Pathogenic variants in COL4A3, COL4A4, or
COL4A5 accounted for 55% (11 of 20) of
cases associated with a single gene; most were
found in COL4A5.
In 17 of the 24 families (71%), 15 pathogenic
mutations in COL4A3, COL4A4, or
COL4A5—9 of them novel—were identiﬁed.

Causative variants were detected in 61.3% of
index patients and others of uncertain clinical
signiﬁcance in 12.5%. Most (88%) variants
were in PKD1 and 12% were in PKD2. Overall,
80 of 158 variants (50.6%) were not reported in
prior studies, indicating wide allelic
heterogeneity.

Abbreviations: ADPKD, autosomal dominant polycystic kidney disease; APOL1, apolipoprotein L1; CKD, chronic kidney disease; CLCN5, chloride voltage-gated
channel 5; COL4A, collagen type IV α-chain; FSGS, focal segmental glomerulosclerosis; MYOE1, myosin 1E; NGS, next-generation sequencing; PKD, polycystic
kidney disease; PTPRO, protein tyrosine phosphatase receptor type O; WES, whole exome sequencing.

identified. Evaluation of gene function, protein-protein
interactions, and phenotypic differences between probands and parents demonstrated that COL4A3 variants were
involved in the progression of diabetic kidney disease.46
In a 2019 study, Groopman et al44 isolated DNA from
3,315 patients with CKD of any cause and performed
proband-only WES on the samples obtained. Genetic
causes were identified in 307, or nearly 10%, of the 3,315
patients, and 30% of patients with a genetic finding were
discovered to have abnormalities in the COL4A genes.44
Among the patients discovered to have COL4A mutations,
62% had been misdiagnosed with clinical diagnoses such
Kidney Med Vol 4 | Iss 4 | Month 2022 | 100435

as FSGS, hypertensive nephropathy, or unspecified glomerulopathy before the study or had not been diagnosed
with Alport syndrome or thin basement membrane nephropathy.44 These results illustrate the potential for genetic findings to provide new clinical insight, with
implications for medical management.
Cameron-Christie et al47 evaluated the potential of WES
for detection of causal genes for nephropathy in a large
cohort of 3,150 patients with broad clinical subcategories
of CKD and a control cohort of 9,563 healthy, unrelated
individuals. They applied a collapsing analysis to evaluate
the contribution of rare variants to CKD in the case
5
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Table 3. Results With Whole Exome Sequencing in Patients With CKD
Study
Groopman et al 201944

Participants
3,315 patients with CKD

Lata et al 201845

92 adults with CKD of unknown
cause, familial nephropathy, or
hypertension

Wang et al 201846

9 MODY probands with biopsy-proven
DKD and their families

Cameron-Christie et al 201947

3,150 patients with broad clinical
subcategories of CKD and a control
cohort of 9,563 healthy, unrelated
individuals

Yamamoto et al 201748

Single family with medullary cystic
kidney disease

Tang et al 201949

2 patients with infantile
nephronophthisis, and 3 patients had
juvenile nephronophthisis

Key Results
Genetic causes were identiﬁed in 307, or nearly 10%, of
the 3,315 patients, and 30% of patients with a genetic
ﬁnding were discovered to have abnormalities in the
COL4A genes. Among the patients discovered to have
COL4A mutations, 62% had been misdiagnosed before
the study or had not been diagnosed with Alport
syndrome or TBMN.
WES provided a diagnosis in 24% of patients, which
included 9 probands with CKD of unknown cause and 13
distinct genetic disorders. Loss-of-function mutations
were identiﬁed in PARN in 2 probands with
tubulointerstitial ﬁbrosis.
Evaluation of gene function, protein-protein interactions,
and phenotypic differences between probands and
parents demonstrated that COL4A3 variants were
involved in the progression of DKD.
The genes PKD1, PKD2, and COL4A5 reached
signiﬁcance across the entire cohort with CKD, whereas
COL4A3 and COL4A4 were highly ranked across
multiple analysis models. Signals in COL4A3, COL4A4,
and COL4A5 emerged in the combined cohort,
suggesting that rare variations in these genes might
contribute to many clinical forms of nephropathy.
WES demonstrated a novel frameshift mutation before
the variable number of tandem repeat region in the
MUC1 gene.
The 2 patients with infantile nephronophthisis had
NPHP3 mutations, with one carrying compound
heterozygous mutations (c.1358A>G, c.2369A>G) and
the other simultaneously carrying a c.1174C>T IVS263A>G cleavage site mutation from the father and a
nonsense mutation (p.392R>X, 939) from the mother.
Two patients with juvenile nephronophthisis had
frameshift mutations (c.1583 to 1596: deletion) and
homozygous point mutations (7 c.640G>T) of the
NPHP1 gene. The ﬁfth patient had a complex
heterozygous mutation of the NPHP2 gene
(c.2686G>A, c.1943A>G).

Abbreviations: CKD, chronic kidney disease; COL4A, collagen type IV α-chain; DKD, diabetic kidney disease; MODY, maturity-onset diabetes of the young; MUC1,
mucin 1; NPHP, nephrocystin; PARN, poly(A)-speciﬁc ribonuclease; PKD, polycystic kidney disease; TBMN, thin basement membrane nephropathy; WES, whole
exome sequencing.

samples.47 The genes PKD1, PKD2, and COL4A5 reached
significance across the entire cohort with CKD, whereas
COL4A3 and COL4A4 were highly ranked across multiple
analysis models. Signals in COL4A3, COL4A4, and COL4A5
emerged in the combined cohort, suggesting that rare
variations in these genes may contribute to many clinical
forms of nephropathy.47
Whole Genome Sequencing (WGS) in CKD
The WGS approach detects DNA variations outside the
exons that can lead to genetic disorders, namely in the
introns and noncoding regions. Such variations are not
detected by WES, which focuses only on the exons.
WGS detects complex trait variants, including copy
number variants and variants in genes situated in
intronic and other noncoding segments of the
genome.10,31,50
WGS results from 2 large databases were used to measure the frequency of high-confidence mutations presumed to be causative in ADPKD and autosomal dominant
6

polycystic liver disease and to estimate lifetime ADPKD
prevalence using strict criteria for defining rare variants in
genes involved in ADPKD (PKD1, PKD2), autosomal dominant polycystic liver disease (PRKCSH, SEC63, GANAB, ALG8,
SEC61B, LRP5), and potential cystic disease modifiers.51
Determination of high-confidence pathogenic mutations
in WGS resulted in a lower boundary for lifetime prevalence of ADPKD of 9.3 cases per 10,000 sequenced. Genes
potentially relevant as cyst modifiers and truncating mutations in autosomal dominant polycystic liver disease
genes were identified in 103.9 and 20.2 per 10,000
sequenced, respectively. A greater-than-expected frequency of loss-of-function mutations in autosomal dominant polycystic liver disease genes also suggested the
possibility of unrecognized cases and incomplete
penetrance.51
WGS has also been used to detect genetic differences in
a cohort of Finnish siblings with type 1 diabetes who were
discordant for the presence or absence of diabetic nephropathy. Control patients had diabetes for 15-37 years
Kidney Med Vol 4 | Iss 4 | Month 2022 | 100435
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Table 4. Results With Whole Genome Sequencing in Patients With CKD
Study
Lanktree et al 201851

Participants
Results from 2 large databases were used to
measure the frequency of high-conﬁdence
mutations presumed to be causative in ADPKD
and ADPLD

Guo et al 202052

Finnish siblings with type 1 diabetes who were
discordant for the presence or absence of
diabetic nephropathy

Larrue et al 202053

2 patients with nephronophthisis

Levine et al 202054

146 patients with primary
membranoproliferative GN and 6,442
individuals without kidney disease (controls)

Key Results
Genes potentially relevant as cyst modiﬁers and
truncating mutations in ADPLD genes were identiﬁed in
103.9 and 20.2 per 10,000 sequenced, respectively. A
greater-than-expected frequency of loss-of-function
mutations in ADPLD genes also suggested the possibility
of unrecognized cases and incomplete penetrance.
Diabetic nephropathy-associated variants were enriched
in a network representing proteins essential for podocyte
function when clustered at the gene level and include
protein kinases and protein tyrosine kinase 2.
WGS identiﬁed 2 putative disease-causing intronic
mutations in the NPHP3 gene, including one deep
intronic variant. Both affected splicing, resulting in a
truncated nephrocystin-3 protein.
A signiﬁcant common variant locus was identiﬁed at
6p21.32 (rs35406322) overlapping the HLA locus.

Abbreviations: ADPKD, autosomal dominant polycystic kidney disease; ADPLD, autosomal dominant polycystic liver disease; CKD, chronic kidney disease;
GN, glomerulonephropathy; HLA, human leukocyte antigen; NPHP3, nephrocystin 3; WGS, whole genome sequencing.

without any complications. Results indicated that when
clustered at the gene level, diabetic nephropathy-associated
variants were enriched in a network representing proteins
fundamental for podocyte function, including protein kinases and protein tyrosine kinase 2.52 Several new genes
were found to be strongly associated with diabetic nephropathy, including PRKCE, PTK1, PRKCI, ABTB1, and
ALOX5. The significant association with protein kinase
genes is especially intriguing, strongly implicating the
protein kinase C family in the pathogenesis of diabetic
nephropathy and suggesting protein kinase C inhibitors as
attractive novel therapies.52 Studies using WGS are summarized in Table 4.53,54
CLINICAL RELEVANCE OF GENETIC TESTING IN
CKD
To translate genetic findings into improved patient care,
longitudinal studies of large cohorts of individuals with
genetic diagnoses are required. Long-term follow-up is
needed for patients who have participated in NGS studies
to examine the role of genetic information on clinical
management, health care utilization, and outcomes.55
There are a few published examples of genetic information guiding treatment strategy, and further studies are
needed; however, Table 5 provides examples of the clinical
utility of a genetic diagnosis of kidney disease.56-73 As
noted earlier, because a genetic cause is implicated in
nearly all children who receive kidney replacement therapy
and in approximately 10% of adults (including 964 of
3,315 patients [29%] aged ≥65 years in the study by
Groopman et al44), it can be offered to appropriate patients
of varying age groups.22
Prognosis
Age-adjusted total kidney volume represented by the Mayo
imaging classification estimates an individual’s unique rate
Kidney Med Vol 4 | Iss 4 | Month 2022 | 100435

of kidney growth and offers an individualized approach to
prognostication in ADPKD.74 Genetic assessment of patients with ADPKD also demonstrated that most with PKD1
protein-truncating in-frame indels or mutations were at
elevated risk of CKD progression and were likely to benefit
from new treatments.75 One example may include the use
of medications, such as tolvaptan, a selective vasopressin
V2 receptor antagonist that delays the increase in kidney
cyst volume and thereby prevents CKD progression as well
as pain due to cysts.76,77 Another example is bardoxolone
methyl, a novel nuclear erythroid 2–related factor activator
under clinical development that improves mitochondrial
function and has an anti-inflammatory action in ADPKD.78
Conversely, some patients with PKD2 or nontruncating
PKD1 mutations are unlikely to reach kidney failure by 60
years of age, and such patients can be reassured that
conventional treatment (such as inhibition of the reninangiotensin-aldosterone system) and control of proteinuria and hypertension may be sufficient.75
Diagnosis
Gene panel testing has the potential to provide a genetic
diagnosis in a substantial number of patients with suspected Alport syndrome or steroid-resistant nephrotic
syndrome, and it should be undertaken early during care.
Testing using NGS should have the capacity to detect copy
number variants for genes associated with these conditions.79 Clinical genetic testing has the potential to stratify
patients and support clinical decision making regarding
their care.79 Such patients may benefit from more detailed
WGS to better identify pathogenetic factors for therapeutic
targeting (such as COQ2 defects that code for proteins in
the coenzyme Q10 pathway, as mentioned above).79
Identification of a pathogenic variant may also result in
modification or elimination of immunosuppressive treatments and augment rational planning for immunosuppression after kidney transplant.20,79
7
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Table 5. Clinical Impact of Genetic Testing in Kidney Diseases
Indication
Steroid-resistant
nephrotic
syndrome

Genetic Finding
Homozygous Fin-major
mutation in NPHS1
COQ2 mutation

COL4A3 or COL4A4
missense mutation

Cystic renal
dysplasia

17q12 deletion

Nephrolithiasis

APRT mutation

Episodic
hypertension

SDHD mutation

Failure to thrive,
G6PC mutation
hepatomegaly, and
hyperuricemia

Genetic Diagnosis
Nephrotic syndrome type 1
(OMIM #256300)
CoQ10 deﬁciency 1 (OMIM
#607426)

Clinical Impact
Increased risk of posttransplant
disease recurrence
CoQ10 supplementation can
attenuate proteinuria and
extrarenal complications such
as encephalopathy
• Distinguishes between autoAlport syndrome (OMIM
#104200; #203780) or TBMD somal (COL4A3 or
COL4A4) and X-linked
(OMIM #141200)
(COL4A5) inheritance,
informing family counseling
• Missense
mutations
are
associated with less severe
disease and slower progression to kidney failure and lossof-function mutations
• Avoids immunosuppression (a
commonly used therapy for
nephrotic syndrome)
Renal cysts and diabetes
Multisystem work-up for
syndrome (OMIM #137920)
associated extrarenal
complications, including testing
for diabetes, exocrine
pancreatic insufﬁciency,
hepatic function, neurologic
anomalies, and/or
neurocognitive impairment
APRT deﬁciency (OMIM
Xanthine dehydrogenase
#614723)
inhibition to prevent crystalline
nephropathy and allograft loss
• Imaging studies to screen for
Hereditary paragangliomaadditional tumors
pheochromocytoma syndrome
• Catecholamine antagonists
(OMIM #168000)
and/or surgical tumor
resection
• Knowledge of parent-of-origin
effect due to maternal
imprinting informs genetic
counseling
• Lower risk of malignancy than
other genetic causes of familial paragangliomapheochromocytoma
syndromes informs prognosis
• Dietary therapy (frequent
Glycogen storage disease Ia
meals, nasogastric tube, and/
(OMIM #232200)
or raw starch to prevent hypoglycemia; oral bicarbonate
and avoidance of fructose
and glucose to prevent
acidosis)
• Surveillance for hepatic adenoma; liver transplant may be
needed

References
57, 58
59, 60

61-64

65-67

68, 69
70, 71

72, 73

Note: Reproduced from Groopman et al56 with permission of Springer Nature.
Abbreviations: APRT, adenine phosphoribosyltransferase; COL4A, collagen type IV α-chain; CoQ10, coenzyme Q10; COQ2, coenzyme Q2, polyprenyltransferase;
G6PC, glucose-6-phosphatase catalytic subunit; NPHS1, nephrin; SDHD, succinate dehydrogenase complex subunit D; TBMD, thin basement membrane disease.

Thrombotic microangiopathy, which includes atypical
HUS, thrombotic thrombocytopenic purpura, and Shiga
toxin–associated HUS, requires prompt diagnosis because
of differing pathophysiology and importance of early
treatment for thrombotic thrombocytopenic purpura and
atypical HUS.80 In atypical HUS, a rare variant of
8

thrombotic microangiopathy, several studies have
demonstrated heterozygous pathogenic activating mutations in the genes encoding the alternative pathway components C3 and factor B and loss-of-function mutations in
the genes encoding the regulators FH (including CFH/
CFHR fusions), FI, and CD46.81 Because the genetic
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mutations are predisposing versus causative with incomplete penetrance, additional disease risk modifiers and
environmental triggers (eg, pregnancy, infection) may be
contributory.81 Eculizumab is a recombinant humanized
monoclonal antibody that can be tailored to the patient
once a diagnosis of atypical HUS has been confirmed.28
Variants of Uncertain Signiﬁcance
Genetic testing may result in the identification of variants
of uncertain significance, which represent variants with
insufficient evidence to determine the role in disease. The
American College of Medical Genetics and Genomics
guidelines note that such variants should not be used in
clinical decision making82; however, some institutional
policies require reporting of variants of uncertain significance to patients.83 One study found that the diagnostic
yield of 250 exome sequencing samples increased from
24.8% to 46.8% after manual review of available data just
5 years later.84 Retrospective identification of clinically
relevant (or irrelevant) variants, therefore, requires
continual review of emerging data, which may be
augmented by semiautomated processes.84
Genetic Testing and Kidney Biopsy
In addition to clarifying the diagnosis in CKD of unknown
etiology, genetic testing may obviate the need for kidney
biopsy in some patients. In a 2021 study of 204 patients
with suspected hereditary CKD, WES identified a molecular
diagnosis in 80 (39%) patients, including 10 (13%) for
whom genetic testing negated the need for a kidney biopsy.85 In a retrospective analysis of 273 patients who
underwent kidney transplantation that evaluated a
genetics-first approach in improving diagnosis of kidney
failure in patients younger than 50 years, targeted WES
resulted in a genetic diagnosis in 21%-51% of patients.
Among those who received a kidney biopsy for diagnosis
of CKD before study enrollment, biopsy results would have
provided no additional diagnostic value for 43% of patients if genetic testing had been performed first.86
Genetic Counseling
Pre- and posttest counseling is recommended for all patients who undergo genetic testing, regardless of the
modality used.83 Pretest counseling provides patients and
their families with an understanding of the opportunities
and limitations of genetic testing and ensures that
informed consent is obtained.83,87 Posttest counseling
should be provided by a licensed genetic counselor and
offers guidance for patients on the implications of their
testing results for disease risk and management, psychosocial implications, and recommendations for family
screening.83,87 Guidelines are available from the American
College of Medical Genetics and Genomics to support
discussions on the interpretation of sequence variants
based on supporting evidence for the role in disease
pathogenicity.82
Kidney Med Vol 4 | Iss 4 | Month 2022 | 100435

Genetic Testing Services
Genetic testing for kidney diseases is available through
various companies including, but not limited to, Invitae
Corporation, Natera, Inc, and Centogene US, LLC.88-90
Invitae offers a Progressive Renal Disease Panel that analyzes 195 genes for kidney disorders such as Alport syndrome, FSGS, and nephrotic syndrome. Natera, through
Renasight, tests 385 genes associated with CKD to assess a
patient’s genetic cause for kidney disease or whether there
is an increased hereditary risk due to family history.
Centogene provides genetic testing for >300 different
genes associated with inherited kidney-related diseases.
There may also be clinical and academic studies enrolling
patients that provide genetic testing; otherwise, patients
are recommended to inquire with their local genetic
counselors or the National Society of Genetic Counselors
for more information.91,92
Other Clinical Considerations
A genetic diagnosis is important but can be accompanied by
challenges such as physician education, sequence reanalysis,
and return on results.56 Additionally, there may be clinical
challenges for patients with CKD of unclear etiology whose
genetic test determines a diagnosis that is currently without
treatment or ongoing clinical trials. In these instances,
providing continued clinical follow-up, communication
about relevant ongoing research, and directing the patient
and family to genetic counseling and advocacy support
groups can add important value to the patient’s care.

CASE STUDY VIGNETTE
Unlike other kidney diseases, genetic testing is rarely
performed in patients with ADPKD.93 The importance of
genetic testing in PKD was reported by Cornec-Le Gall
et al94 in a 7-generation pedigree, which yielded a diagnosis of 2 different cystic disorders. Targeted NGS of 65
candidate genes in a patient with an ADPKD-like phenotype without a familial PKD2 mutation yielded a COL4A1
mutation and a diagnosis of hereditary angiopathy with
nephropathy, aneurysms, and muscle cramps syndrome.
This case demonstrates the utility of targeted NGS in differential diagnoses and identifying disease variability. An
accurate diagnosis of ADPKD will be important to optimize
patient care and management.
CONCLUSION
Precision medicine has the potential to considerably
improve care for patients with CKD. Accurate diagnosis,
prognosis—and to a lesser extent—decisions on treatment
have already been advanced by genetic assessment of patients with CKD, most notably with NGS, including targeted gene panels, WES, and WGS. These now widely
available and relatively low-cost approaches have shown
novel genetic variants in previously unrecognized biological pathways, highlighting disease mechanisms with a
9
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potential role in CKD etiology, morbidity, and mortality.
Combining data obtained from the NGS approaches
described in this review with clinical phenotypic results
from large and diverse cohorts will help define
genotype-phenotype relationships for different types of
CKD and support individualized approaches to treatment.
Nephrologists can benefit from understanding the advantages of NGS and genotype-phenotype relationships in
patients with CKD and the factors inducing variability in
each disease and the same causative mutation. With
decreasing costs of high-throughput sequencing, new
discoveries are likely, and genetic testing could become a
commonly available and affordable resource for routine
clinical care. The optimal application of genomics in the
prevention and treatment of CKD requires the adoption of
this mode of investigation by practicing nephrologists
across the health care spectrum. Whereas the benefits of
genetic assessment in patients with kidney disease have
been recognized by nephrologists who manage pediatric
patients,14 the advantages of precision medicine including
genetic evaluation with NGS should be extended to adult
patients with CKD to pinpoint causes of disease and
rationally guide therapy.15
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